
==== Front
Mycopathologia
Mycopathologia
Mycopathologia
0301-486X
1573-0832
Springer Netherlands Dordrecht

39264513
887
10.1007/s11046-024-00887-6
Review
Metagenomics Applied to the Respiratory Mycobiome in Cystic Fibrosis
http://orcid.org/0000-0001-7641-3002
Angebault Cécile cecile.angebault@aphp.fr

12
Botterel Françoise 12
1 https://ror.org/033yb0967 grid.412116.1 0000 0001 2292 1474 Unité de Parasitologie-Mycologie, Département de Prévention, Diagnostic et Traitement des Infections, Hôpitaux Universitaires Henri Mondor, Assistance Publique des Hôpitaux de Paris (APHP), Créteil, France
2 grid.410511.0 0000 0001 2149 7878 Dynamyc UR 7380, USC Anses, Ecole Nationale Vétérinaire d’Alfort (ENVA), Faculté de Santé, Univ. Paris-Est Créteil (UPEC), Créteil, France
Handling Editor: Jessica S. Little.

12 9 2024
12 9 2024
2024
189 5 8210 5 2024
21 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Cystic fibrosis (CF) is a genetic disorder characterized by chronic microbial colonization and inflammation of the respiratory tract (RT), leading to pulmonary exacerbation (PEx) and lung damage. Although the lung bacterial microbiota has been extensively studied, the mycobiome remains understudied. However, its importance as a contributor to CF pathophysiology has been highlighted. The objective of this review is to provide an overview of the current state of knowledge regarding the mycobiome, as described through NGS-based studies, in patients with CF (pwCF).

Several studies have demonstrated that the mycobiome in CF lungs is a dynamic entity, exhibiting a lower diversity and abundance than the bacterial microbiome. Nevertheless, the progression of lung damage is associated with a decrease in fungal and bacterial diversity. The core mycobiome of the RT in pwCFs is mainly composed of yeasts (Candida spp., Malassezia spp.) and molds with lower abundance. Some fungi (Aspergillus, Scedosporium/Pseudallescheria) have been demonstrated to play a role in PEx, while the involvement of others (Candida, Pneumocystis) remains uncertain. The “climax attack” ecological model has been proposed to explain the complexity and interplay of microbial populations in the RT, leading to PEx and lung damage. NGS-based studies also enable the detection of intra- and interkingdom correlations between fungi and bacteria. Further studies are required to ascertain the biological and pathophysiological relevance of these correlations. Finally, with the recent advent of CFTR modulators, our understanding of the pulmonary microbiome and mycobiome in pwCFs is about to change.

Keywords

Cystic fibrosis mycobiome
Next-generation sequencing
Fungi
http://dx.doi.org/10.13039/501100006342 Association Vaincre la Mucoviscidose issue-copyright-statement© Springer Nature B.V. 2024
==== Body
pmcIntroduction

Cystic fibrosis (CF) is one of the most prevalent genetic disorders associated with chronic airway colonization and infections, as well as reduced life expectancy, particularly in Europe, North America and Australia [1, 2]. The reduced mucociliary clearance and inflammation of the airways facilitate the chronic microbial colonization of the respiratory tract (RT) by microorganisms that have adapted to this specific microenvironment [3]. Bacteria, and to a lesser extent, fungi, contribute to recurrent pulmonary exacerbations (PExs), which require anti-infective treatments and result in a progressive decline in respiratory function [1, 4, 5]. For many years, the study of the mycobiota has been based on culture-based studies with a particular focus on the fungi involved in PEx. Aspergillus and Pseudallescheria/Scedosporium have been demonstrated to be the most frequently encountered molds in PEx, typically manifesting as the disease progresses [2, 6]. Rare fungi, including Exophiala dermatitidis, Lomentospora prolificans and Rasamsonia argillacae, have also been linked to PEx in patients with CF (pwCFs) [7]. Candida yeasts and related genera are frequently isolated from oral and respiratory samples of pwCFs, and they are considered to be colonizers [2, 6–8]. Nevertheless, some authors have observed an increased prevalence of PEx and a decline in lung function in patients with persistent Candida colonization. The role of these yeasts remains unclear to date [7, 9–11]. In recent years, culture-independent methods based on next-generation sequencing (NGS), such as metagenomics, have significantly advanced our understanding of the microbiome. It has enabled the identification of species that cannot be cultured or that are present in low abundance, thereby facilitating a more accurate description of fungal (but also bacterial) diversity and the potential correlations between microorganisms within or between kingdoms [12–15]. The principal techniques used are targeted-amplicon NGS (TA-NGS) and shotgun metagenomics (SMg). Both methods have inherent limitations in regard to studying the mycobiome, and it is important to be aware of these limitations when analyzing published studies. The airway mycobiome in pwCFs represents a minor fraction, in terms of quantity and diversity, of the total airway microbiome. Consequently, it is not uncommon for these techniques to underdetect the presence of fungi.

The objective of this review is to describe the current state of knowledge regarding fungal colonization and infection in CF by linking fungal prevalence data obtained from culture-based studies with those obtained from metagenomic analyses. By integrating these two methodologies, we can enhance our understanding of the role of fungi in CF pathogenesis.

Tools for Metagenomic Studies of the Respiratory Mycobiome

Reference methods used to study the mycobiome in CF or other diseases include targeted-amplicon NGS (TA-NGS) and more recently, shotgun metagenomics (SMg, also called global metagenomics) [16] (Table 1, Fig. 1). These techniques can overcome the biases associated with fungal culture, including fungi that do not grow on standard media, fungal loads that are too low to be detected in culture, and so forth. Consequently, they yield more comprehensive insights into fungal diversity [12, 13, 17, 18]. Nevertheless, certain challenges in investigating the RT mycobiome through NGS-based approaches have been identified. Firstly, the mycobiome represents a small proportion of the total human microbiome. Estimates suggest that it constitutes less than 1% of the microbial metagenome, which itself represents less than 1% of the total host–microbe metagenome [19]. Furthermore, the extraction of fungal nucleic acids is challenging due to the protection of fungal cells by a thick wall composed of complex polysaccharides (chitin, ß-glucan polymers, etc.) and sometimes melanin. It has been demonstrated that significant biases in the diversity of the mycobiome can be observed depending on the extraction technique used [2–4]. In order to obtain a good extraction yield, different lysis methods must be combined including mechanical lysis, which is an essential step and is carried out using beads of different sizes, chemical lysis and enzymatic lysis [21]. When analyzing the mycobiome in pwCFs, it is also important to consider the type of respiratory specimen used (sputum or bronchoalveolar lavage) and its potential dilution, which could affect the detection of the mycobiome. To date, the most commonly used method in studies of the CF RT mycobiome is TA-NGS [16, 23]. TA-NGS usually targets the internal transcribed spacer (ITS) region, which consists of two subregions (ITS1 and ITS2), each 400 bp long (Table 1). The profile of fungal communities may vary depending on the subregion or the primers chosen [24, 25]. The relative abundance of taxa may also be distorted due to the variable number of copies of the ITS region in fungi [26]. SMg, as a non-targeted approach that allows random sequencing of all types of nucleic acids from hosts and microorganisms, can be used to study all components of a microbiome simultaneously including fungi. It also has the advantage of quantifying the abundance of microorganisms in absolute (rather than relative) terms. However, due to the low quantity of fungal sequences compared to those of the host and other microorganisms (the rare biosphere), the depth of sequencing represents a significant challenge in accurately detecting the mycobiome using SMg [19, 27, 28]. Furthermore, fungal genomes exhibit similarities with those of the host, and some fungal sequences are eliminated during bioinformatic analysis. This may result in an underestimation of the mycobiome. In their study, Pienkowska et al. found that only 0.1% of sequences obtained from RT samples of pwCF were assigned to fungi using SMg [28]. To enhance the sensitivity of SMg for fungal detection, enzymatic depletion (DNase/RNase) of human nucleic acids prior to sequencing can be performed, as can an increase of the depth of sequencing and the combination of DNA and RNA detection [27]. To date, SMg has been employed primarily for clinical metagenomics (panpathogen research from a given sample [27, 29]) or to study the bacterial or viral microbiome. A limited number of studies have been published on the RT mycobiome in pwCFs using SMg (n = 9 original articles listed in PubMed NCBI on March 24, 2024). Regardless of the NGS-based approach employed, the accurate taxonomic annotation of fungal sequences remains a challenge [30]. Fungal taxonomy is evolving, and many fungi have multiple names, which may change rapidly. Fungal databases are also far from complete (whether they are sequence or complete genome databases). Furthermore, the use of TA-NGS or SMg necessitates the use of environmental controls (DNA/RNA-free water) in order to detect fungal contamination [16, 27].Table 1 Definitions and abbreviations related to NGS-based methods, such as metagenomic analysis, for studying the mycobiome

ASV	Amplicon Sequence Variant: individual DNA sequences produced by targeted NGS after elimination of poor-quality sequences and use of a sequencing error correction algorithm (e.g., DADA2). All ASV are then assigned to a taxonomic identification. ASVs are an alternative to OTUs	
Alpha-diversity	An estimate of the diversity of a given sample taking into account richness and evenness. Simpson and Shannon indexes are common alpha-diversity indexes	
Beta-diversity	An estimate of the difference in community composition between different samples (e.g., two anatomical sites, two individuals, etc.). It can be evaluated through principal component or coordinate analysis (PCA/PCoA)	
Core mycobiome	Taxa, genera or species present in the majority (generally > 50%) of individuals in the same group with a relative abundance > 0.1%	
Fungal dysbiosis	Imbalance in the composition of the mycobiota compared with the steady state (eubiosis) detected in healthy subjects	
Evenness	Evaluation of the distribution of species/taxa/OTUs/ASVs present in a sample, taking into account the relative abundance of the different groups	
Shannon or Simpson diversity indexes	Indexes measuring the alpha-diversity of a community's composition, taking into account both richness and evenness	
OTU	Operational Taxonomic Unit: cluster of sequences obtained from targeted-amplicon NGS using a pipeline (e.g., VSEARCH) that clusters sequences with a high percentage of similarity (> 97%). The OTUs are then assigned to a taxonomic identification (or taxon)	
Richness	Evaluation of the number of species, taxa, OTUs or ASVs present in a sample, without taking into account the relative abundance between the different groups	
Shotgun metagenomics (SMg)	Global metagenomics: study of all components of microbiome (bacterial, viral, fungal and other eukaryotes) at once using a nontargeted approach	

Fig. 1 Methods used to study the airway mycobiome in CF patients. Figure adapted from Thornton et al. J Pediatric Infect Dis Soc. 2022 [15] and created with BioRender.com. Abbreviations: ASV amplicon sequence variant; NGS next-generation sequencing; OTU operational taxonomic unit; TA-NGS targeted-amplicon NGS; SMg shotgun metagenomics

It is also important to note that, while metagenomic methods are valuable for studying the diversity of the respiratory mycobiome in pwCF in depth, they are not a replacement for culture-based methods. Indeed, culture-based studies have the advantage of readily identifying the predominant fungal agents in the respiratory tract, distinguishing living fungi from circulating DNA, and facilitating more comprehensive investigations of fungal strains (determination of susceptibility to antifungal agents, search for resistance genes or virulence factors, genotyping for strain comparison, etc.). The culture-based and culture-independent method are therefore ideally suited to complementary use.

Basics of Mycobiota in the Respiratory Tract of PwCFs

A Specific Microenvironment that Favors Colonization by Adapted Microorganisms

In the airways of pwCFs, dysfunction of the CF transmembrane conductance regulator (CFTR) channel leads to reduced fluidification of mucus on epithelial cells (Fig. 2) [3, 31–33]. A thicker and more viscous mucus leads to an environment enriched with nutrients (such as glycoproteins), a reduction in airway oxygenation (hypoxia), and a defect in mucociliary clearance, which favors the growth of some microorganisms (such as Pseudomonas aeruginosa or anaerobes) [34, 35]. Other specific features of the CF airway microenvironment can provide a breeding ground for chronic colonization with adapted microorganisms. These include a reduction in pH due to a lack of bicarbonates, an increase in bile acid levels due to frequent aspirations that favors biofilm formation, an elevation in iron levels that favors microbial growth, a deficiency in NO production by CFTR-epithelial cells, and so forth (Fig. 2). In addition, pwCFs may exhibit persistent inflammation due to constitutive activation of the NF-kB pathway in CFTR-epithelial cells, which is associated with an excessive innate immune response against chronic colonizing microorganisms. Consequently, the increased production of proinflammatory cytokines and neutrophil recruitment, elevated oxidative stress, impaired macrophage phagocytosis, and increased lysis ability impede the effective microbial clearance, yet exacerbate tissue damage (Fig. 2) [3, 31–33].Fig. 2 Airway-specific microenvironment in patients with CF. The different specificities of the CF airway microenvironment favor chronic colonization with adapted microorganisms, allowing possible intra- and interkingdom interactions (through biofilm formation and molecular interactions) and leading to repeated pulmonary exacerbations (PEx). Its association with persistent inflammation leads to lung damage and respiratory failure. Abbreviations: Mφ: macrophage; Neut: neutrophil.

Adapted from Ubags and Marsland, Eur Respir J. 2017 [31]. The figure was created with BioRender.com

Knowledge From Culture-Based Studies Regarding Fungi in the Airways of PwCFs

A substantial body of data regarding the prevalence of colonization or infection by fungi in pwCFs has been collected through culture studies. These data have been collected on a large scale, involving national and international cohorts, such as the European CF Society (ECFS, https://www.ecfs.eu/ecfspr), the French national cohort (“Vaincre la Mucoviscidose” project [2]), the United States CF Foundation Patient Registry [36], and so forth. Candida albicans and Aspergillus fumigatus have been identified as the most prevalent fungi detected in the RT of pwCFs, with prevalence varying with age [2, 36, 37]. In France, in 2022, C. albicans was the most prevalent fungus in the RT of pwCF, with a prevalence of 10–15% in children under the age of 5 and approximately 30% in adolescents and adults (> 15 years) [2]. A. fumigatus was the second most common fungus, with a prevalence of less than 5% in children under 5 years of age, which increased to approximately 15% after 10 years of age [2]. The prevalence of these fungi in the CF population as a whole also varies according to country and center, geographical or environmental criteria [9, 37]. In Europe, during the 2012–2016 period, the prevalence of A. fumigatus was 4% in the Czech Republic, 13% in Poland, 29% in Italy and 42% in Austria [38]. More recently (2019), a Dutch study reported an A. fumigatus prevalence of 56% [39]. The overall prevalence of C. albicans varies from 30% to > 70% in European countries [37, 38]. Other rarer fungi with variable prevalence are found in the RT of pwCFs. The prevalence of the black yeast Exophiala dermatitidis varies from < 1% in the United Kingdom, Italy or the Czech Republic to 15–20% in Sweden [37, 38, 40]. The species from the Scedosporium/Pseudallescheria complex represent the second most common mold in the RT of pwCF (prevalence of 2–17%). Species of the Rasamsonia argillacea complex or Lomentospora prolificans are less prevalent (< 5% for both) [37, 38, 40, 41]. Some authors have also studied the variations in fungal prevalence in the RT of pwCFs according to seasonal or climatic changes [42, 43], as has been demonstrated for CF bacteria such as P. aeruginosa [44]. Furthermore, the prevalence of fungi has been observed to vary depending on the period under study, with a tendency towards a reduction in fungal prevalence over time. For instance, the mean prevalence of A. fumigatus in France was 25% in 2015, 22% in 2021 and 12% in 2022 [2, 45]. These changes may be partially attributed to the novel use of CFTR modulators in the treatment of CF [46, 47].

Role of Yeasts and Filamentous Fungi in CF Lung Mycobiome in the Metagenomic Era

As demonstrated by several authors, the NGS-based approach allows for a more comprehensive description of the mycobiota diversity in pwCFs and enables the detection of fungal colonization at lower RT with greater sensitivity [13, 17]. In a study by Botterel et al., it was observed that the median number of fungal genera detected using TA-NGS in the sputa of pwCFs was 8, while it was 2 according to culture [13]. Delhaes et al. demonstrated that 60% of fungal taxa detected by NGS were undetected in culture [12]. Cuthberston et al. demonstrated that the NGS-based approach allowed for the detection of four major CF fungi (Candida, Aspergillus, Scedosporium and Exophiala) with a prevalence 3–24 times higher than that detected by culture. It is, however, important to note that the positivity cutoff for fungal sequences in this study was particularly low since a sample with only one sequence was considered positive [17].

Diversity, Fungal Burden and Evolution of the Lung Mycobiome in PwCFs Through Age, PEx and Disease Progression

The fungal load and diversity of the RT mycobiome in pwCFs are significantly lower than those of the bacterial mycobiome [13, 14]. However, the total fungal load in pwCFs is higher than that of healthy controls, regardless of age [48]. Additionally, the fungal burden also appears to increase with age, while its diversity decreases with disease progression, as has been previously observed for the bacterial microbiota [12, 13, 15, 48–50]. This reduction in diversity can be observed from the first months after diagnosis (i.e., from birth for some pwCFs) and is correlated with the decline of the respiratory function, which is evaluated through spirometry parameters, forced expiratory volume in one second (FEV1) and forced vital capacity (FVC), and/or the CF-specific questionnaire (CFQ-R [51]) [12, 22, 48–50]. NGS-based studies have also demonstrated the occurrence of a fungal dysbiosis in the lungs of pwCFs compared to controls [13, 17]. Even when compared with patients who have bronchiectasis due to other causes, the diversity of the mycobiome appears to be different, with reduced fungal alpha-diversity in pwCFs [17]. Some authors have also studied the composition and diversity of the mycobiome in pwCFs during the PEx [15, 52]. Hong et al. observed that the global composition of the fungal community differed between pwCF in the stable state and PEx (beta-diversity, Table 1) [52]. Soret et al. analyzed the median alpha-diversity scores of fungal communities during the PEx or in a stable state and demonstrated a decreasing trend in diversity in patients during the PEx [15].

Core Mycobiome in the Respiratory Tract of PwCFs

The definition of the core microbiome may vary depending on the author [53, 54]. However, the fundamental principle is to identify a set of constant and/or stable microbial components within a population, in contrast to the microorganisms of transient flora, which vary according to environmental, individual or exogenous conditions [53]. The core mycobiome is defined as a group of fungal taxa that are shared by most individuals (generally > 50%) and have a relative abundance greater than 0.1%. The initial studies on the core mycobiome were relatively recent and focused primarily on the digestive core mycobiome. Only a few studies have been published regarding the respiratory core mycobiome, whether in healthy subjects or pathological conditions (such as asthma, bronchiectasis, CF, lung cancer, etc.). Moreover, given the variability of the mycobiome across ecological niches, it is of great important to identify the specific site under investigation.

NGS-based studies have shown that the core mycobiome of the lower RT in pwCF is predominantly composed of yeasts belonging to the Saccharomycotina subphylum, including Candida, Debaryomyces, Pichia, and Saccharomyces. These yeasts are frequently associated with Malassezia spp. [15, 17, 48, 52, 55]. Among the Candida species, C. albicans is the most prevalent, followed by Candida dubliniensis and Candida parapsilosis, as also described in culture studies [52, 56]. This core mycobiome is comparable to that observed in the lower RT [57, 58] and the gastrointestinal tract of healthy subjects [24, 59]. Some molds are also detected in the majority of pwCFs (in particular, Aspergillus, Cladosporium, Penicillium) but at lower relative abundances than yeasts [14, 17, 58, 60]. This result differs from what is known from culture, where A. fumigatus has the second highest fungal prevalence after C. albicans [2, 37, 38, 40]. NGS-based studies have revealed a specific picture of the core mycobiota of the RT of pwCF, with an even greater prevalence and diversity of Saccharomycotina yeasts and a much lower abundance of Aspergillus. This may appear counterintuitive, given the established role of Aspergillus in PEx and allergic bronchopulmonary aspergillosis (ABPA) in pwCFs [2, 37, 38, 61]. Other fungi frequently described in pwCFs by culture, such as Scedosporium or Exophiala, are also detected using NGS-based approaches [17]. However, the prevalence of these fungi varies greatly depending on the study, as is also the case in culture-based studies [40, 41, 62], and they may or may not be considered part of the core mycobiome [15, 17, 60]. For instance, Cuthberston et al. reported a prevalence of 48% and 54% for Scedosporium and Exophiala, respectively (samples were considered positive when ≥ 1 fungal sequence was detected), Soret et al. reported a prevalence of 42% and 6%, respectively, and Kramer et al. reported a prevalence of 4% and 4%, respectively [14, 15, 17]. In the study by O’Connor et al., no sequences of Exophiala or Scedosporium were detected using NGS [48]. These discrepancies can be attributed not only to contextual dissimilarities between studies (geographical location of the study, year of the study) but also to variations in the design and the NGS-based protocol employed.

Overall, the core mycobiome described in pwCF is consistent with the hypothesis that the mycobiota of the lower RT is probably of mixed origin. A major part is derived from salivary microaspirations, as has been demonstrated for the bacterial microbiota [63], consistent with yeast predominance resembling the digestive mycobiota. A minor part is derived from inhaled airborne fungal flora (transient flora), which remains in limited quantities in the lung. However, as the mucociliary clearance system is impaired in the RT of pwCFs, the overall abundance of inhaled fungi is higher than that in healthy individuals [17, 48].

Role of Candida and Saccharomycotina Yeasts in the Mycobiota of PwCFs

Although yeasts from the subphylum Saccharomycotina, including Candida spp., are highly prevalent in the upper and lower RTs of pwCFs according to culture and NGS studies, their precise role in pathophysiology remains unclear [7]. C. albicans followed by C. dubliniensis are the most frequently detected Candida species in the RT of pwCFs by culture, and they are mainly considered as colonizers [38, 64]. Nevertheless, some authors have suggested possible association between Candida spp. colonization and a decline in respiratory function and general health [10, 11, 36, 65]. For instance, Chotirmall et al. demonstrated that patients colonized with C. albicans exhibited lower BMIs and decreased FEV1 and FVC [65]. This finding was corroborated in a large cohort of pwCFs by Gileles-Hillel et al., who also observed a greater rate of annual decline in FEV1 in pwCFs chronically colonized with C. albicans [11]. This study also demonstrated that C. albicans colonization was associated with chronic colonization by other CF pathogens, including P. aeruginosa and A. fumigatus. Furthermore, the authors identified potential contributing factors to C. albicans colonization, including pancreatic insufficiency and diabetes [11]. In an NGS-based study, Hong et al. observed an increased rate of C. dubliniensis in patients with a PEx. In addition, a higher ratio of C. dubliniensis to C. albicans was observed in patients with PEx, which was also associated with a lower respiratory score (evaluated through the CFQ-R [51]). The role of Candida spp. in the decline of lung functions remains unclear. One possible explanation could be that the yeasts directly affect the lung parenchyma (e.g., by invading the tissue after switching to hyphae) or exacerbate the local inflammation due to their pro-inflammatory effect, as previously demonstrated for C. albicans in the digestive tract [19, 66]. Candida spp. may also have potential deleterious synergistic association or interaction with other pathogens involved in tissue damage, such as P. aeruginosa. This could occur through the production of mixed biofilm, induction of antimicrobial tolerance, and other mechanisms. Alternatively, Candida spp. might simply have a predilection for already damaged tissues [67–70].

Role of Aspergillus fumigatus and Other Filamentous Fungi in the Mycobiota of PwCFs

Among fungi, A. fumigatus has the greatest impact on pwCF and lung function decline and is implicated in several diseases, particularly in allergic bronchopulmonary aspergillosis (ABPA), Aspergillus sensitization or bronchitis, or even invasive aspergillosis in immunocompromised pwCF (e.g., solid organ transplantation) [2, 7, 61, 71]. The prevalence of ABPA in pwCFs (based on culture-based studies and national CF registries) varies considerably depending on age and country (3–25%), with a pooled prevalence estimated at 8.9% in children and 10.1% in adults (as determined by Maturu et al. from the data of 45 CF studies) [61, 71]. Oher mold species, including Scedosporium/Pseudallescheria spp., Lomentospora prolificans and Rasamsonia spp., have been identified as potential causes of allergic bronchopulmonary disease and may also pose a threat in immunocompromised pwCF [41, 72–76]. In contrast, the clinical role of other fungi associated with CF, such as Exophiala sp. remains to be clearly determined [38, 40, 77] In a Swedish culture-based study, a high prevalence of Exophiala sp. was reported, and an association was found with a more advanced form of the disease [62]. But these results were not confirmed, and a recent Dutch study concluded that Exophiala sp. is probably only a minor pathogen in CF [40].

A Specific Focus on Pneumocystis jirovecii in the RT of PwCFs

NGS-based studies theoretically allow the detection of fungi that are uncultivable, such as Pneumocystis jirovecii. However, the majority of studies employing NGS-based methods do not report the presence of P. jirovecii in RT samples of pwCFs [12–15, 48, 52, 78]. In TA-NGS-based studies, this may be due to the fact that P. jirovecii has only one copy of the rDNA operon (including the ITS region) in contrast to other fungi which have several repeats of the ITS region [26]. In SMg studies, the overall detection of fungal sequences is very low which makes it difficult to provide a precise description of the mycobiome [28, 79]. Only a few authors have studied P. jirovecii in pwCFs, with the majority of studies focusing specifically on this microorganism [60, 80–86]. In a recent multicenter Spanish study on the lung mycobiome in pwCF, the authors added a specific qPCR for P. jirovecii detection (targeting the mt-LSU rRNA region) and reported a 31% prevalence of colonization [60]. Overall, the prevalence of P. jirovecii in pwCF varies considerably between studies [60, 80–87]. For instance, a prevalence of approximately 8% (7.4 and 8.1%) was observed in Germany and in the United Kingdom, while it was of 38.2% in Brazil [83–85]. In France, the prevalence of P. jirovecii exhibited regional variations, with rates below 4% in Brittany and 12% in other regions [80–82]. In Spain, the prevalence reported increased from 21.6% in 2005 to 31% in 2023 [60, 86]. These discrepancies may be explained by the prior exposure of pwCF to cotrimoxazole, as well as differences in the antibiotic protocols used at distinct CF centers [82, 83]. This phenomenon can also result from differences in the age of patients as well as exposure risk factors associated with climate, geographic or environmental context [81]. The role of P. jirovecii in the pathophysiology of CF-related lung decline remains unclear. Green et al. observed an increase in the prevalence of P. jirovecii in pwCF samples during PEx (9.2%) compared with patients in the stable state (2%) [83]. In contrast, Hernández-Hernández et al. reported that pwCF who were colonized with P. jirovecii had less severe lung diseases [80]. In all cases, colonization with P. jirovecii represents a risk of pneumocystosis for pwCFs undergoing lung transplantation [87].

Mycobiome Variations Between Pwcfs According to Geographical Factors or CF Centers

The distribution of CF fungi (other than P. jirovecii) varies according to geographic area or CF center. A geographical gradient of fungal species among European countries has been described by Delhaes et al. in a culture-based study. Candida spp., A. fumigatus, Cladosporium and Penicillium were more prevalent at higher latitudes, while Scedosporium and Lomentospora were more prevalent in southern centers [9]. In a Spanish multicenter study based on multiple Sanger sequencing, Martínez-Rodríguez et al. also observed significant differences in the distribution of fungi between centers (Seville, Madrid, Mallorca), particularly for taxa of lower abundance including Scedosporium spp. and Exophiala spp. [60]. In France, Angebault et al. reported different median relative abundances of A. fumigatus in pwCFs attending two CF centers (unpublished data). As previously discussed for P. jirovecii, these discrepancies in fungal distribution may be attributed to varying exposure levels associated with climate, geographic or environmental factors [41]. Van Rhijn et al. observed that the indoor and outdoor level of Aspergillus spores in a CF center was increased during summer, when temperatures were high and wind speeds low [42, 88]. However, other factors may also contribute to variations in the fungal distribution between centers, including the age of patients (adult, pediatric or mixed population), the type of mutation (homozygous/heterozygous), the severity of the disease, and the differences in antimicrobial protocols from one center to another. To better understand these differences, further international studies including large cohorts of pwCFs from different centers are necessary.

The Lung Mycobiome of PwCFs With Fungal Pulmonary Diseases

To date, only a limited number of studies have used NGS-based methods to describe the dynamics of the mycobiome in pwCFs with pulmonary fungal diseases, including ABPA, Aspergillus sensitization, and fungal bronchitis. Cuthbertson et al. conducted a study in which they compared the mycobiomes of groups of pwCFs with ABPA, fungal bronchitis or no active fungal disease [17]. The authors observed that A. fumigatus was the most predominant taxon only in pwCFs with fungal bronchitis. Furthermore, an increased relative abundance of Scedosporium sp. and Clavispora sp. was observed in pwCFs with ABPA, whereas Exophiala and Candida showed an increased relative abundance in pwCFs with fungal bronchitis [17].

Understanding the “Climax-Attack” Model in CF Airways

The “Climax-Attack” model (CAM) was initially described by Conrad et al. [89]. It proposes an ecological vision that considers the complexity of the lung CF bacterial microbiota and the polymicrobial nature of chronic CF airway infection. It was then refined by Quinn et al., who focused mainly on the functional and metabolic aspects of bacterial communities, and Soret et al., who explored the role of fungi in the model [15, 90]. The CAM proposes the existence of two major functional microbial communities. Microbial interactions between these communities during PEx could explain the changes in the lung microbiota and the progressive reduction in microbial diversity over time (Fig. 3). The climax communities comprise persistent, slow-growing microbial and fungal "keystone" populations that are well adapted to the CF airway microenvironment. The bacterial climax species have metabolic pathways based on amino acid transformation (as a major carbon source) through deamination, which leads to the production of ammonia and an increase in pH, which help maintain community stability [90]. These communities can also produce mixed biofilms, which protect them from the host immune response and antimicrobial treatments. The original or pioneer climax communities are composed of Staphylococcus aureus, Haemophilus sp., respiratory anaerobic bacteria, and possibly also nonpathogenic fungi, such as Penicillium sp. Over time, with the emergence of the attack communities and the recurrence of PEx, the climax communities will evolve, and new species that are better adapted to the specific CF microenvironment will replace the pioneer species. The new climax species include P. aeruginosa (mucoid strains), Stenotrophomonas maltophilia, Achromobacter sp., and possibly fungi such as Scedosporium sp. These species are generally resistant to conventional antimicrobial therapy. On the other hand, attack communities are transient microbial populations that induce strong innate immune responses, leading to acute PEx and lung damage. These communities utilize carbohydrates as an important source of carbon through fermentation pathways, which results in the production of organic acids and a decreased pH. Their emergence favors the instability of the community structure and facilitates the establishment of new climax species. A variety of microorganisms, including viruses (e.g., rhinovirus, influenza, adenovirus, etc.), non-mucoid P. aeruginosa, Staphylococcus sp., Streptococcus sp. and anaerobic bacteria may be part of the attack communities and are often environmentally acquired. Some fungi, such as A. fumigatus, may also be part of attack communities. The species belonging to the attack communities may possess specific virulence factors and elicit intense inflammation. The complete list of species belonging to the climax or attack communities, along with their interrelationships, remains to be established. Some species may be part of both types of communities, such as P. aeruginosa or some anaerobic bacteria, and some species may have changed groups. Some fungal species, such as Candida sp., E. dermatitidis and P. jirovecii, are not yet included in the CAM. In summary, the CAM appears to be an accurate model for describing the interrelationships between two types of polymicrobial communities, which could explain the occurrence of PEx in pwCFs, the progression of the disease, and the change in microbiota diversity over time.Fig. 3 The “Climax-Attack” model for CF airways. The “Climax-Attack model” is an ecological model adapted to explain the progressive loss of microbial diversity and the replacement of pioneer communities by adapted communities to CF airways. The figure was adapted from the articles of Quinn et al. npj Biofilms Microbiomes. 2016; Soret et al. Sci Rep. 2020; Conrad et al. Am J Respir Cell Mol Biol 2013 [15, 89, 90] and created, in part, with BioRender.com

Intra- and Interkingdom Correlation Networks in PwCFs

NGS-based studies of the mycobiome (and microbiome) allow the detection of possible positive or negative intra- or interkingdom correlations (co-occurrence or co-exclusion between fungi and/or bacteria). This is achieved by constructing a correlation matrix from the entire set of microbial data. The correlation matrix can then be represented graphically as a correlation network [91]. Some authors have constructed correlation networks for the bacterial microbiome of pwCFs, but few have done so for the mycobiome or to study possible bacterial-fungal correlations [15, 48, 90]. In their study of the fungal and bacterial microbiomes of 33 pwCFs, Soret et al. observed several interkingdom correlations (at the genus level) between fungi and bacteria. In particular, they observed three clusters centered on Aspergillus, Candida and Scedosporium, which showed positive or negative correlations with different bacteria [15]. Among all the statistical correlations identified, the authors selected one between Aspergillus and Streptococcus for in vitro testing to determine the biological relevance and potential for a real interaction. Their findings demonstrated that Aspergillus growth was enhanced by two species of Streptococcus. Angebault et al. also constructed correlation networks based on the fungal and bacterial microbiomes of 56 pwCFs, identifying other correlations between fungi and bacteria (unpublished data). To date, an increasing number of interactions between microorganisms (intra- or interkingdom) have been explored in the CF context. These interactions can vary widely in nature and include direct physical interactions, mixed biofilm production, quorum-sensing-related interactions, bacterial release of volatile organic compounds, competition for nutrients and siderophores, changes in susceptibility to antimicrobial agents, and so forth [69, 92]. For example, several interactions between A. fumigatus and P. aeruginosa or S. maltophilia or between C. albicans and P. aeruginosa have been elucidated [67, 68, 92–97]. Intra- and interkingdom correlation analysis based on NGS microbiome studies may highlight possible unknown interactions between microorganisms, but these interactions must be tested in experimental models to verify their biological relevance.

The New Era of CFTR Modulators and Their Effects on the Mycobiome

Symptomatic therapies have long been employed to treat inflammation, lung dysfunction and chronic airway infections in pwCFs. The advent of CFTR modulators has led to remarkable improvements in lung function and health status in approximately 90% of the CF population, depending on the mutation(s) carried [98–100]. Among other effects, the use of CFTR modulators has led to significant changes in the respiratory bacterial microbiome of pwCFs including increased bacterial richness, alpha diversity and reduced rates of specific pathogens, such as P. aeruginosa [101–104]. Regarding fungi, different authors have demonstrated that CFTR modulators have the potential to reduce the rate of colonization by Aspergillus [32, 47, 103–105]. Heltshe et al. reported a significant reduction in the number of pwCFs positive for Aspergillus in their sputa during the year following the introduction of CFTR potentiator, ivacaftor [104]. Bessonova et al. utilized the CF national registries from the USA and the UK to report a decrease in the prevalence of Aspergillus colonization between patients treated with and without ivacaftor [105]. Frost et al. observed a reduction in the prevalence of Aspergillus colonization over three years in patients treated with ivacaftor [103]. Chesnay et al. also observed a reduction in Aspergillus-positive cultures in pwCFs under combined CFTR modulators (elexacaftor/tezacaftor/ivacaftor) [47]. The authors also demonstrated a reduction in the amount of anti-Aspergillus precipitating IgG and total IgE [47]. This finding suggests a potential effect of CFTR modulators on APBA and Aspergillus sensitization [47]. In an experimental study, Currie et al. showed that CFTR modulators do not have a direct fungicidal effect on Aspergillus. Nevertheless, they have been demonstrated to reduce the production of reactive oxygen species by CF phagocytes in the presence of Aspergillus [106]. The available data on changes in the overall mycobiome (taxonomic composition, diversity, and dynamics) due to CFTR modulators are currently limited [32]. Following the bacterial and fungal microbiota of 41 pwCFs for six months after the introduction of CFTR modulators (lumacaftor/ivacaftor), Enaud et al. observed no changes in the fungal (or bacterial) load, α- or β-fungal (bacterial) diversity or the abundance of specific taxa [107]. In contrast, Hong et al. observed an increased fungal α-diversity among pwCFs treated with CFTR modulators as compared to those without [52]. It is hypothesized that the observed changes in the respiratory mycobiome are linked to improved lung function and reduced chronic inflammation resulting from the restoration of CFTR channel functions. Further studies on the long-term effects of CFTR modulators on the lung mycobiome are necessary.

Conclusion

To date, the NGS-based approaches used for studying the mycobiome of the RT in pwCFs are mostly TA-NGS. For the time being, SMg methods have limitations in describing the lung mycobiome due to the difficulty in precisely identifying microbial communities of low abundance (low fungal load). Many variations have been described in mycobiome studies. This can be explained not only by geographical data but also by variations in the design and the NGS-based protocol chosen. The pathophysiological role of Candida spp. and Saccharomycotina yeasts, as well as P. jirovecii in the context of CF, remains to be determined. As for the bacterial microbiome, the diversity of the RT mycobiome decreases over time in pwCFs, as recurrent PEx occur and lung damage progresses. NGS-based studies permit the identification of correlations between microorganisms within and between kingdoms, which may lead to the discovery of novel interactions between microorganisms in the CF context. The climax-attack model has been proposed to describe the complexity of the lung CF bacterial and fungal microbiota and explain their dynamics of change over time. With the use of CFTR modulators, significant changes in the mycobiome (and microbiome) of pwCFs are anticipated in the coming years. Consequently, it will be essential to continue investigating the mycobiome of RT in pwCFs.

Key Research Questions About the RT Mycobiome in CF

Technical improvement of metagenomics protocols (design, universal targets, databases, bioinformatics pipelines, standardization, etc.) for mycobiome analysis

Contribution of TA-NGS and SMg to determining prevalence of yeast and filamentous fungi compared to culture-based methods

Use of RT mycobiome (detected through TA-NGS or SMg) for diagnostic or prognostic purposes in CF

Understanding the role of all prevalent fungi in CF (including Candida, Malassezia, Exophiala, P. jirovecii, etc.)

Geographic environment, age, exacerbation or CFTR modulators in the evolution of RT mycobiome

Bacterial and fungal associations in the RT of pwCF: mixed biofilms and therapeutic implications

Authors Contribution

CA wrote the manuscript. FB supervised and corrected the manuscript.

Use of generative AI for manuscript preparation

All content was written by CA and FB. English grammar and turns of phrase were revised with the help of DeepL and Curie.

Funding

This review was written as an addendum to a study entitled "Ecologie et dynamique des communautés bactériennes et fongiques des voies aériennes supérieures des patients atteints de mucoviscidose”, which received a grant from the “Vaincre La Mucoviscidose” Foundation (Grant Number: 2013/2013–047/03, https://www.vaincrelamuco.org/). The funders were not involved in the review of the literature or the preparation of the manuscript.

Declarations

Competing interest

The authors have no conflicts of interest to declare.

Ethics Approval

Not applicable.

Consent to Participate

Not applicable.

Consent to Publish

Not applicable.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Elborn JS Cystic fibrosis Lancet 2016 388 2519 2531 10.1016/S0140-6736(16)00576-6 27140670
Elborn JS. Cystic fibrosis. Lancet. 2016;388:2519–31.27140670 10.1016/S0140-6736(16)00576-6
2. Vaincre la Mucoviscidose. Registre français de la mucoviscidose - Bilan des données 2022. https://www.vaincrelamuco.org/registredelamuco. 2022.
3. Rossi GA Morelli P Galietta LJ Colin AA Airway microenvironment alterations and pathogen growth in cystic fibrosis Pediatr Pulmonol 2019 54 497 506 10.1002/ppul.24246 30620146
Rossi GA, Morelli P, Galietta LJ, Colin AA. Airway microenvironment alterations and pathogen growth in cystic fibrosis. Pediatr Pulmonol. 2019;54:497–506.30620146 10.1002/ppul.24246
4. Flume PA VanDevanter DR Burgel P-R Contoli M López-Campos JL Cystic fibrosis: definition, severity and impact of pulmonary exacerbations Acute Exacerbations of Pulmonary Diseases 2017 European Respiratory Society 25 37
Flume PA, VanDevanter DR. Cystic fibrosis: definition, severity and impact of pulmonary exacerbations. In: Burgel P-R, Contoli M, López-Campos JL, editors. Acute Exacerbations of Pulmonary Diseases. European Respiratory Society; 2017. p. 25–37. 10.1183/2312508X.10015716.
5. Thornton CS Parkins MD Microbial epidemiology of the cystic fibrosis airways: past, present, and future Semin Respir Crit Care Med 2023 44 269 286 10.1055/s-0042-1758732 36623820
Thornton CS, Parkins MD. Microbial epidemiology of the cystic fibrosis airways: past, present, and future. Semin Respir Crit Care Med. 2023;44:269–86.36623820 10.1055/s-0042-1758732
6. Tracy MC Moss RB The myriad challenges of respiratory fungal infection in cystic fibrosis Pediatr Pulmonol 2018 53 S75 85 10.1002/ppul.24126 29992775
Tracy MC, Moss RB. The myriad challenges of respiratory fungal infection in cystic fibrosis. Pediatr Pulmonol. 2018;53:S75-85.29992775 10.1002/ppul.24126
7. Schwarz C Hartl D Eickmeier O Hector A Benden C Durieu I Progress in definition, prevention and treatment of fungal infections in cystic fibrosis Mycopathologia 2018 183 21 32 10.1007/s11046-017-0182-0 28762125
Schwarz C, Hartl D, Eickmeier O, Hector A, Benden C, Durieu I, et al. Progress in definition, prevention and treatment of fungal infections in cystic fibrosis. Mycopathologia. 2018;183:21–32.28762125 10.1007/s11046-017-0182-0
8. Francis F Enaud R Soret P Lussac-Sorton F Avalos-Fernandez M MucoFong investigation group, et al. new insights in microbial species predicting lung function decline in CF: lessons from the MucoFong project J Clin Med 2021 10 3725 10.3390/jcm10163725 34442021
Francis F, Enaud R, Soret P, Lussac-Sorton F, Avalos-Fernandez M. MucoFong investigation group, et al. new insights in microbial species predicting lung function decline in CF: lessons from the MucoFong project. J Clin Med. 2021;10:3725.34442021 10.3390/jcm10163725
9. Delhaes L Touati K Faure-Cognet O Cornet M Botterel F Dannaoui E Prevalence, geographic risk factor, and development of a standardized protocol for fungal isolation in cystic fibrosis: results from the international prospective study “MFIP” J Cyst Fibros 2019 18 212 220 10.1016/j.jcf.2018.10.001 30348610
Delhaes L, Touati K, Faure-Cognet O, Cornet M, Botterel F, Dannaoui E, et al. Prevalence, geographic risk factor, and development of a standardized protocol for fungal isolation in cystic fibrosis: results from the international prospective study “MFIP.” J Cyst Fibros. 2019;18:212–20.30348610 10.1016/j.jcf.2018.10.001
10. Chotirmall SH O’Donoghue E Bennett K Gunaratnam C O’Neill SJ McElvaney NG Sputum Candida albicans presages FEV1 decline and hospital-treated exacerbations in cystic fibrosis Chest 2010 138 1186 1195 10.1378/chest.09-2996 20472859
Chotirmall SH, O’Donoghue E, Bennett K, Gunaratnam C, O’Neill SJ, McElvaney NG. Sputum Candida albicans presages FEV1 decline and hospital-treated exacerbations in cystic fibrosis. Chest. 2010;138:1186–95.20472859 10.1378/chest.09-2996
11. Gileles-Hillel A Shoseyov D Polacheck I Korem M Kerem E Cohen-Cymberknoh M Association of chronic Candida albicans respiratory infection with a more severe lung disease in patients with cystic fibrosis Pediatr Pulmonol 2015 50 1082 1089 10.1002/ppul.23302 26383963
Gileles-Hillel A, Shoseyov D, Polacheck I, Korem M, Kerem E, Cohen-Cymberknoh M. Association of chronic Candida albicans respiratory infection with a more severe lung disease in patients with cystic fibrosis. Pediatr Pulmonol. 2015;50:1082–9.26383963 10.1002/ppul.23302
12. Delhaes L Monchy S Frealle E Hubans C Salleron J Leroy S The airway microbiota in cystic fibrosis: a complex fungal and bacterial community-implications for therapeutic management PLoS ONE 2012 7 e36313 10.1371/journal.pone.0036313 22558432
Delhaes L, Monchy S, Frealle E, Hubans C, Salleron J, Leroy S, et al. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community-implications for therapeutic management. PLoS ONE. 2012;7:e36313.22558432 10.1371/journal.pone.0036313
13. Botterel F Angebault C Cabaret O Stressmann FA Costa J-M Wallet F Fungal and bacterial diversity of airway microbiota in adults with cystic fibrosis: concordance between conventional methods and ultra-deep sequencing, and their practical use in the clinical laboratory Mycopathologia 2018 183 171 183 10.1007/s11046-017-0185-x 28766039
Botterel F, Angebault C, Cabaret O, Stressmann FA, Costa J-M, Wallet F, et al. Fungal and bacterial diversity of airway microbiota in adults with cystic fibrosis: concordance between conventional methods and ultra-deep sequencing, and their practical use in the clinical laboratory. Mycopathologia. 2018;183:171–83.28766039 10.1007/s11046-017-0185-x
14. Kramer R Sauer-Heilborn A Welte T Guzman CA Abraham W-R Höfle MG Cohort study of airway mycobiome in adult cystic fibrosis patients: differences in community structure between fungi and bacteria reveal predominance of transient fungal elements J Clin Microbiol 2015 53 2900 10.1128/JCM.01094-15 26135861
Kramer R, Sauer-Heilborn A, Welte T, Guzman CA, Abraham W-R, Höfle MG. Cohort study of airway mycobiome in adult cystic fibrosis patients: differences in community structure between fungi and bacteria reveal predominance of transient fungal elements. J Clin Microbiol. 2015;53:2900.26135861 10.1128/JCM.01094-15
15. Soret P Vandenborght L-E Francis F Coron N Enaud R Avalos M Respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis Sci Rep 2020 10 3589 10.1038/s41598-020-60015-4 32108159
Soret P, Vandenborght L-E, Francis F, Coron N, Enaud R, Avalos M, et al. Respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis. Sci Rep. 2020;10:3589.32108159 10.1038/s41598-020-60015-4
16. Thornton CS Acosta N Surette MG Parkins MD Exploring the cystic fibrosis lung microbiome: making the most of a sticky situation J Pediatric Infect Dis Soc 2022 11 S13 22 10.1093/jpids/piac036 36069903
Thornton CS, Acosta N, Surette MG, Parkins MD. Exploring the cystic fibrosis lung microbiome: making the most of a sticky situation. J Pediatric Infect Dis Soc. 2022;11:S13-22.36069903 10.1093/jpids/piac036
17. Cuthbertson L Felton I James P Cox MJ Bilton D Schelenz S The fungal airway microbiome in cystic fibrosis and non-cystic fibrosis bronchiectasis J Cyst Fibros 2021 20 295 302 10.1016/j.jcf.2020.05.013 32540174
Cuthbertson L, Felton I, James P, Cox MJ, Bilton D, Schelenz S, et al. The fungal airway microbiome in cystic fibrosis and non-cystic fibrosis bronchiectasis. J Cyst Fibros. 2021;20:295–302.32540174 10.1016/j.jcf.2020.05.013
18. McDermott G Walsh A Crispie F Frost S Greally P Cotter PD Insights into the adolescent cystic fibrosis airway microbiome using shotgun metagenomics Int J Mol Sci 2024 25 3893 10.3390/ijms25073893 38612702
McDermott G, Walsh A, Crispie F, Frost S, Greally P, Cotter PD, et al. Insights into the adolescent cystic fibrosis airway microbiome using shotgun metagenomics. Int J Mol Sci. 2024;25:3893.38612702 10.3390/ijms25073893
19. Iliev ID Cadwell K Effects of intestinal fungi and viruses on immune responses and inflammatory bowel diseases Gastroenterology 2021 160 1050 1066 10.1053/j.gastro.2020.06.100 33347881
Iliev ID, Cadwell K. Effects of intestinal fungi and viruses on immune responses and inflammatory bowel diseases. Gastroenterology. 2021;160:1050–66.33347881 10.1053/j.gastro.2020.06.100
20. Angebault C Payen M Woerther P-L Rodriguez C Botterel F Combined bacterial and fungal targeted amplicon sequencing of respiratory samples: does the DNA extraction method matter? PLoS ONE 2020 15 e0232215 10.1371/journal.pone.0232215 32343737
Angebault C, Payen M, Woerther P-L, Rodriguez C, Botterel F. Combined bacterial and fungal targeted amplicon sequencing of respiratory samples: does the DNA extraction method matter? PLoS ONE. 2020;15: e0232215.32343737 10.1371/journal.pone.0232215
21. Huseyin CE Rubio RC O’Sullivan O Cotter PD Scanlan PD The Fungal Frontier: a comparative analysis of methods used in the study of the human gut mycobiome Front Microbiol 2017 8 1432 10.3389/fmicb.2017.01432 28824566
Huseyin CE, Rubio RC, O’Sullivan O, Cotter PD, Scanlan PD. The Fungal Frontier: a comparative analysis of methods used in the study of the human gut mycobiome. Front Microbiol. 2017;8:1432.28824566 10.3389/fmicb.2017.01432
22. Angebault C Ghozlane A Volant S Botterel F d’Enfert C Bougnoux M-E Combined bacterial and fungal intestinal microbiota analyses: impact of storage conditions and DNA extraction protocols PLoS ONE 2018 13 e0201174 10.1371/journal.pone.0201174 30074988
Angebault C, Ghozlane A, Volant S, Botterel F, d’Enfert C, Bougnoux M-E. Combined bacterial and fungal intestinal microbiota analyses: impact of storage conditions and DNA extraction protocols. PLoS ONE. 2018;13: e0201174.30074988 10.1371/journal.pone.0201174
23. Gangneux J-P Guegan H Vandenborght L-E Buffet-Bataillon S Enaud R Delhaes L A European ECMM-ESCMID survey on goals and practices for mycobiota characterisation using next-generation sequencing Mycoses 2019 62 1096 1099 10.1111/myc.12999 31498487
Gangneux J-P, Guegan H, Vandenborght L-E, Buffet-Bataillon S, Enaud R, Delhaes L. A European ECMM-ESCMID survey on goals and practices for mycobiota characterisation using next-generation sequencing. Mycoses. 2019;62:1096–9.31498487 10.1111/myc.12999
24. Nash AK Auchtung TA Wong MC Smith DP Gesell JR Ross MC The gut mycobiome of the human microbiome project healthy cohort Microbiome 2017 5 153 10.1186/s40168-017-0373-4 29178920
Nash AK, Auchtung TA, Wong MC, Smith DP, Gesell JR, Ross MC, et al. The gut mycobiome of the human microbiome project healthy cohort. Microbiome. 2017;5:153.29178920 10.1186/s40168-017-0373-4
25. Dellière S Dannaoui E Fieux M Bonfils P Gricourt G Demontant V Analysis of microbiota and mycobiota in fungal ball rhinosinusitis: specific interaction between Aspergillus fumigatus and Haemophilus influenza? Journal of Fungi 2021 7 550 10.3390/jof7070550 34356929
Dellière S, Dannaoui E, Fieux M, Bonfils P, Gricourt G, Demontant V, et al. Analysis of microbiota and mycobiota in fungal ball rhinosinusitis: specific interaction between Aspergillus fumigatus and Haemophilus influenza? Journal of Fungi. 2021;7:550.34356929 10.3390/jof7070550
26. Nahimana A Francioli P Blanc DS Bille J Wakefield AE Hauser PM Determination of the copy number of the nuclear rDNA and beta-tubulin genes of Pneumocystis carinii f. sp. hominis using PCR multicompetitors J Eukaryot Microbiol 2000 47 368 372 10.1111/j.1550-7408.2000.tb00062.x 11140450
Nahimana A, Francioli P, Blanc DS, Bille J, Wakefield AE, Hauser PM. Determination of the copy number of the nuclear rDNA and beta-tubulin genes of Pneumocystis carinii f. sp. hominis using PCR multicompetitors. J Eukaryot Microbiol. 2000;47:368–72.11140450 10.1111/j.1550-7408.2000.tb00062.x
27. d’Humières C Salmona M Dellière S Leo S Rodriguez C Angebault C The potential role of clinical metagenomics in infectious diseases: therapeutic perspectives Drugs 2021 10.1007/s40265-021-01572-4 34328626
d’Humières C, Salmona M, Dellière S, Leo S, Rodriguez C, Angebault C, et al. The potential role of clinical metagenomics in infectious diseases: therapeutic perspectives. Drugs. 2021. 10.1007/s40265-021-01572-4.34328626 10.1007/s40265-021-01572-4
28. Pienkowska K Pust M-M Gessner M Gaedcke S Thavarasa A Rosenboom I The cystic fibrosis upper and lower airway metagenome Microbiol Spectr 2023 11 e0363322 10.1128/spectrum.03633-22 36892308
Pienkowska K, Pust M-M, Gessner M, Gaedcke S, Thavarasa A, Rosenboom I, et al. The cystic fibrosis upper and lower airway metagenome. Microbiol Spectr. 2023;11: e0363322.36892308 10.1128/spectrum.03633-22
29. Rodriguez C Jary A Hua C Woerther P-L Bosc R Desroches M Pathogen identification by shotgun metagenomics of patients with necrotizing soft-tissue infections Br J Dermatol 2020 183 105 113 10.1111/bjd.18611 31610037
Rodriguez C, Jary A, Hua C, Woerther P-L, Bosc R, Desroches M, et al. Pathogen identification by shotgun metagenomics of patients with necrotizing soft-tissue infections. Br J Dermatol. 2020;183:105–13.31610037 10.1111/bjd.18611
30. Lind AL Pollard KS Accurate and sensitive detection of microbial eukaryotes from whole metagenome shotgun sequencing Microbiome 2021 9 58 10.1186/s40168-021-01015-y 33658077
Lind AL, Pollard KS. Accurate and sensitive detection of microbial eukaryotes from whole metagenome shotgun sequencing. Microbiome. 2021;9:58.33658077 10.1186/s40168-021-01015-y
31. Ubags NDJ Marsland BJ Mechanistic insight into the function of the microbiome in lung diseases Eur Respir J 2017 50 1602467 10.1183/13993003.02467-2016 28893867
Ubags NDJ, Marsland BJ. Mechanistic insight into the function of the microbiome in lung diseases. Eur Respir J. 2017;50:1602467.28893867 10.1183/13993003.02467-2016
32. Bercusson A Jarvis G Shah A CF fungal disease in the age of CFTR modulators Mycopathologia 2021 186 655 664 10.1007/s11046-021-00541-5 33813719
Bercusson A, Jarvis G, Shah A. CF fungal disease in the age of CFTR modulators. Mycopathologia. 2021;186:655–64.33813719 10.1007/s11046-021-00541-5
33. Cohen TS Prince A Cystic fibrosis: a mucosal immunodeficiency syndrome Nat Med 2012 18 509 519 10.1038/nm.2715 22481418
Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med. 2012;18:509–19.22481418 10.1038/nm.2715
34. Dickson RP Erb-Downward JR Huffnagle GB Homeostasis and its disruption in the lung microbiome Am J Physiol Lung Cell Mol Physiol 2015 309 L1047 L1055 10.1152/ajplung.00279.2015 26432870
Dickson RP, Erb-Downward JR, Huffnagle GB. Homeostasis and its disruption in the lung microbiome. Am J Physiol Lung Cell Mol Physiol. 2015;309:L1047–55.26432870 10.1152/ajplung.00279.2015
35. Worlitzsch D Tarran R Ulrich M Schwab U Cekici A Meyer KC Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients J Clin Invest 2002 109 317 325 10.1172/JCI0213870 11827991
Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest. 2002;109:317–25.11827991 10.1172/JCI0213870
36. Granchelli AM Adler FR Keogh RH Kartsonaki C Cox DR Liou TG Microbial interactions in the cystic fibrosis airway J Clin Microbiol 2018 56 e00354 e418 10.1128/JCM.00354-18 29769279
Granchelli AM, Adler FR, Keogh RH, Kartsonaki C, Cox DR, Liou TG. Microbial interactions in the cystic fibrosis airway. J Clin Microbiol. 2018;56:e00354-e418.29769279 10.1128/JCM.00354-18
37. Renner S Nachbaur E Jaksch P Dehlink E Update on respiratory fungal infections in cystic fibrosis lung disease and after lung transplantation Journal of Fungi 2020 6 381 10.3390/jof6040381 33371198
Renner S, Nachbaur E, Jaksch P, Dehlink E. Update on respiratory fungal infections in cystic fibrosis lung disease and after lung transplantation. Journal of Fungi. 2020;6:381.33371198 10.3390/jof6040381
38. Schwarz C Bouchara J-P Buzina W Chrenkova V Dmeńska H de la Pedrosa EGG Organization of patient management and fungal epidemiology in cystic fibrosis Mycopathologia 2018 183 7 19 10.1007/s11046-017-0205-x 29098487
Schwarz C, Bouchara J-P, Buzina W, Chrenkova V, Dmeńska H, de la Pedrosa EGG, et al. Organization of patient management and fungal epidemiology in cystic fibrosis. Mycopathologia. 2018;183:7–19.29098487 10.1007/s11046-017-0205-x
39. Engel TGP Tehupeiory-Kooreman M Melchers WJG Reijers MH Merkus P Verweij PE Evaluation of a new culture protocol for enhancing fungal detection rates in respiratory samples of cystic fibrosis patients J Fungi (Basel) 2020 6 82 10.3390/jof6020082 32526938
Engel TGP, Tehupeiory-Kooreman M, Melchers WJG, Reijers MH, Merkus P, Verweij PE. Evaluation of a new culture protocol for enhancing fungal detection rates in respiratory samples of cystic fibrosis patients. J Fungi (Basel). 2020;6:82.32526938 10.3390/jof6020082
40. de Jong CCM Slabbers L Engel TGP Yntema JB van Westreenen M Croughs PD Clinical relevance of Scedosporium spp. and Exophiala dermatitidis in patients with cystic fibrosis: a nationwide study Med Mycol 2020 58 859 866 10.1093/mmy/myaa003 32030418
de Jong CCM, Slabbers L, Engel TGP, Yntema JB, van Westreenen M, Croughs PD, et al. Clinical relevance of Scedosporium spp. and Exophiala dermatitidis in patients with cystic fibrosis: a nationwide study. Med Mycol. 2020;58:859–66.32030418 10.1093/mmy/myaa003
41. Ravenel K Guegan H Gastebois A Bouchara J-P Gangneux J-P Giraud S Fungal colonization of the airways of patients with cystic fibrosis: the role of the environmental reservoirs Mycopathologia 2024 189 19 10.1007/s11046-023-00818-x 38407729
Ravenel K, Guegan H, Gastebois A, Bouchara J-P, Gangneux J-P, Giraud S. Fungal colonization of the airways of patients with cystic fibrosis: the role of the environmental reservoirs. Mycopathologia. 2024;189:19.38407729 10.1007/s11046-023-00818-x
42. van Rhijn N Coleman J Collier L Moore C Richardson MD Bright-Thomas RJ Meteorological factors influence the presence of fungi in the air; A 14-month surveillance study at an adult cystic fibrosis center Front Cell Infect Microbiol 2021 11 759944 10.3389/fcimb.2021.759944 34900752
van Rhijn N, Coleman J, Collier L, Moore C, Richardson MD, Bright-Thomas RJ, et al. Meteorological factors influence the presence of fungi in the air; A 14-month surveillance study at an adult cystic fibrosis center. Front Cell Infect Microbiol. 2021;11: 759944.34900752 10.3389/fcimb.2021.759944
43. Ziesing S Suerbaum S Sedlacek L Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center Med Mycol 2016 54 781 786 10.1093/mmy/myw035 27364649
Ziesing S, Suerbaum S, Sedlacek L. Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center. Med Mycol. 2016;54:781–6.27364649 10.1093/mmy/myw035
44. Psoter KJ De Roos AJ Wakefield J Mayer JD Rosenfeld M Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis BMC Infect Dis 2017 17 411 10.1186/s12879-017-2511-9 28599639
Psoter KJ, De Roos AJ, Wakefield J, Mayer JD, Rosenfeld M. Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis. BMC Infect Dis. 2017;17:411.28599639 10.1186/s12879-017-2511-9
45. Vaincre la Mucoviscidose. Registre français de la mucoviscidose - Bilan des données 2016. http://www.vaincrelamuco.org/sites/default/files/registre_francais_de_la_mucoviscidose_-_bilan_2015_v4.pdf. 2016.
46. Regard L Martin C Da Silva J Burgel P-R CFTR modulators: current status and evolving knowledge Semin Respir Crit Care Med 2023 44 186 195 10.1055/s-0042-1758851 36535667
Regard L, Martin C, Da Silva J, Burgel P-R. CFTR modulators: current status and evolving knowledge. Semin Respir Crit Care Med. 2023;44:186–95.36535667 10.1055/s-0042-1758851
47. Chesnay A Bailly É Cosson L Flament T Desoubeaux G Advent of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis treatment: what consequences on Aspergillus-related diseases? Preliminary insights J Cyst Fibros 2022 21 1084 1085 10.1016/j.jcf.2022.09.007 36151024
Chesnay A, Bailly É, Cosson L, Flament T, Desoubeaux G. Advent of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis treatment: what consequences on Aspergillus-related diseases? Preliminary insights J Cyst Fibros. 2022;21:1084–5.36151024 10.1016/j.jcf.2022.09.007
48. O’Connor JB Mottlowitz M Kruk ME Mickelson A Wagner BD Harris JK Network analysis to identify multi-omic correlations in the lower airways of children with cystic fibrosis Front Cell Infect Microbiol 2022 12 805170 10.3389/fcimb.2022.805170 35360097
O’Connor JB, Mottlowitz M, Kruk ME, Mickelson A, Wagner BD, Harris JK, et al. Network analysis to identify multi-omic correlations in the lower airways of children with cystic fibrosis. Front Cell Infect Microbiol. 2022;12: 805170.35360097 10.3389/fcimb.2022.805170
49. Frayman KB Armstrong DS Carzino R Ferkol TW Grimwood K Storch GA The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis Thorax 2017 72 1104 1112 10.1136/thoraxjnl-2016-209279 28280235
Frayman KB, Armstrong DS, Carzino R, Ferkol TW, Grimwood K, Storch GA, et al. The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis. Thorax. 2017;72:1104–12.28280235 10.1136/thoraxjnl-2016-209279
50. Coburn B Wang PW Diaz Caballero J Clark ST Brahma V Donaldson S Lung microbiota across age and disease stage in cystic fibrosis Sci Rep 2015 10.1038/srep10241 26047320
Coburn B, Wang PW, Diaz Caballero J, Clark ST, Brahma V, Donaldson S, et al. Lung microbiota across age and disease stage in cystic fibrosis. Sci Rep. 2015. 10.1038/srep10241.26047320 10.1038/srep10241
51. Quittner AL Sawicki GS McMullen A Rasouliyan L Pasta DJ Yegin A Psychometric evaluation of the cystic fibrosis questionnaire-revised in a national sample Qual Life Res 2012 21 1267 1278 10.1007/s11136-011-0036-z 21993695
Quittner AL, Sawicki GS, McMullen A, Rasouliyan L, Pasta DJ, Yegin A, et al. Psychometric evaluation of the cystic fibrosis questionnaire-revised in a national sample. Qual Life Res. 2012;21:1267–78.21993695 10.1007/s11136-011-0036-z
52. Hong G Daniel SG Lee J-J Bittinger K Glaser L Mattei LM Distinct community structures of the fungal microbiome and respiratory health in adults with cystic fibrosis J Cyst Fibros 2023 22 636 643 10.1016/j.jcf.2023.02.003 36822979
Hong G, Daniel SG, Lee J-J, Bittinger K, Glaser L, Mattei LM, et al. Distinct community structures of the fungal microbiome and respiratory health in adults with cystic fibrosis. J Cyst Fibros. 2023;22:636–43.36822979 10.1016/j.jcf.2023.02.003
53. Neu AT Allen EE Roy K Defining and quantifying the core microbiome: challenges and prospects Proc Natl Acad Sci 2021 118 e2104429118 10.1073/pnas.2104429118 34862327
Neu AT, Allen EE, Roy K. Defining and quantifying the core microbiome: challenges and prospects. Proc Natl Acad Sci. 2021;118: e2104429118.34862327 10.1073/pnas.2104429118
54. Risely A Applying the core microbiome to understand host–microbe systems J Anim Ecol 2020 89 1549 1558 10.1111/1365-2656.13229 32248522
Risely A. Applying the core microbiome to understand host–microbe systems. J Anim Ecol. 2020;89:1549–58.32248522 10.1111/1365-2656.13229
55. Enaud R Vandenborght L-E Coron N Bazin T Prevel R Schaeverbeke T The mycobiome: a neglected component in the microbiota-gut-brain axis Microorganisms 2018 10.3390/microorganisms6010022 29522426
Enaud R, Vandenborght L-E, Coron N, Bazin T, Prevel R, Schaeverbeke T, et al. The mycobiome: a neglected component in the microbiota-gut-brain axis. Microorganisms. 2018. 10.3390/microorganisms6010022.29522426 10.3390/microorganisms6010022
56. Lepesqueur LSS Tanaka MH de Lima G MG Chiba SM Mota AJ Santos SF Oral prevalence and antifungal susceptibility of Candida species in cystic fibrosis patients Arch Oral Biol 2020 116 104772 10.1016/j.archoralbio.2020.104772 32474212
Lepesqueur LSS, Tanaka MH, de Lima G MG, Chiba SM, Mota AJ, Santos SF, et al. Oral prevalence and antifungal susceptibility of Candida species in cystic fibrosis patients. Arch Oral Biol. 2020;116:104772.32474212 10.1016/j.archoralbio.2020.104772
57. Ali NABM Ivan FX Aogáin MM Narayana JK Lee SY Lim CL The healthy airway mycobiome in individuals of Asian descent Chest 2021 159 544 548 10.1016/j.chest.2020.09.072 32926873
Ali NABM, Ivan FX, Aogáin MM, Narayana JK, Lee SY, Lim CL, et al. The healthy airway mycobiome in individuals of Asian descent. Chest. 2021;159:544–8.32926873 10.1016/j.chest.2020.09.072
58. Nguyen LDN Viscogliosi E Delhaes L The lung mycobiome: an emerging field of the human respiratory microbiome Front Microbiol 2015 6 89 10.3389/fmicb.2015.00089 25762987
Nguyen LDN, Viscogliosi E, Delhaes L. The lung mycobiome: an emerging field of the human respiratory microbiome. Front Microbiol. 2015;6:89.25762987 10.3389/fmicb.2015.00089
59. Delavy M Sertour N Patin E Le Chatelier E Cole N Dubois F Unveiling Candida albicans intestinal carriage in healthy volunteers: the role of micro- and mycobiota, diet, host genetics and immune response Gut Microbes 2023 15 2287618 10.1080/19490976.2023.2287618 38017705
Delavy M, Sertour N, Patin E, Le Chatelier E, Cole N, Dubois F, et al. Unveiling Candida albicans intestinal carriage in healthy volunteers: the role of micro- and mycobiota, diet, host genetics and immune response. Gut Microbes. 2023;15:2287618.38017705 10.1080/19490976.2023.2287618
60. Martínez-Rodríguez S Friaza V Girón-Moreno RM Gallego EQ Salcedo-Posadas A Figuerola-Mulet J Fungal microbiota dynamics and its geographic, age and gender variability in patients with cystic fibrosis Clin Microbiol Infect 2023 29 539.e1 539.e7 10.1016/j.cmi.2022.11.001 36371030
Martínez-Rodríguez S, Friaza V, Girón-Moreno RM, Gallego EQ, Salcedo-Posadas A, Figuerola-Mulet J, et al. Fungal microbiota dynamics and its geographic, age and gender variability in patients with cystic fibrosis. Clin Microbiol Infect. 2023;29:539.e1-539.e7.36371030 10.1016/j.cmi.2022.11.001
61. Armstead J Morris J Denning DW Multi-country estimate of different manifestations of aspergillosis in cystic fibrosis PLoS ONE 2014 9 e98502 10.1371/journal.pone.0098502 24914809
Armstead J, Morris J, Denning DW. Multi-country estimate of different manifestations of aspergillosis in cystic fibrosis. PLoS ONE. 2014;9: e98502.24914809 10.1371/journal.pone.0098502
62. Kondori N Gilljam M Lindblad A Jonsson B Moore ERB Wenneras C High rate of Exophiala dermatitidis recovery in the airways of patients with cystic fibrosis is associated with pancreatic insufficiency J Clin Microbiol 2011 49 1004 1009 10.1128/JCM.01899-10 21209163
Kondori N, Gilljam M, Lindblad A, Jonsson B, Moore ERB, Wenneras C. High rate of Exophiala dermatitidis recovery in the airways of patients with cystic fibrosis is associated with pancreatic insufficiency. J Clin Microbiol. 2011;49:1004–9.21209163 10.1128/JCM.01899-10
63. Dickson RP Erb-Downward JR Freeman CM McCloskey L Falkowski NR Huffnagle GB Bacterial topography of the healthy human lower respiratory tract MBio 2017 8 e02287 e2316 10.1128/mBio.02287-16 28196961
Dickson RP, Erb-Downward JR, Freeman CM, McCloskey L, Falkowski NR, Huffnagle GB, et al. Bacterial topography of the healthy human lower respiratory tract. MBio. 2017;8:e02287-e2316.28196961 10.1128/mBio.02287-16
64. Baxter CG Moore CB Jones AM Webb AK Denning DW IgE-mediated immune responses and airway detection of Aspergillus and Candida in adult cystic fibrosis Chest 2013 143 1351 1357 10.1378/chest.12-1363 23139075
Baxter CG, Moore CB, Jones AM, Webb AK, Denning DW. IgE-mediated immune responses and airway detection of Aspergillus and Candida in adult cystic fibrosis. Chest. 2013;143:1351–7.23139075 10.1378/chest.12-1363
65. Chotirmall SH Candida albicans in cystic fibrosis: “opening statements presented, let the trial begin” Pediatr Pulmonol 2016 51 445 446 10.1002/ppul.23315 26418834
Chotirmall SH. Candida albicans in cystic fibrosis: “opening statements presented, let the trial begin.” Pediatr Pulmonol. 2016;51:445–6.26418834 10.1002/ppul.23315
66. d’Enfert C Kaune A-K Alaban L-R Chakraborty S Cole N Delavy M The impact of the fungus-host-microbiota interplay upon Candida albicans infections: current knowledge and new perspectives FEMS Microbiol Rev 2021 45 060
d’Enfert C, Kaune A-K, Alaban L-R, Chakraborty S, Cole N, Delavy M, et al. The impact of the fungus-host-microbiota interplay upon Candida albicans infections: current knowledge and new perspectives. FEMS Microbiol Rev. 2021;45:060.
67. Alam F Blackburn SA Davis J Massar K Correia J Tsai H-J Pseudomonas aeruginosa increases the susceptibility of Candida albicans to amphotericin B in dual-species biofilms J Antimicrob Chemother 2023 78 2228 2241 10.1093/jac/dkad228 37522316
Alam F, Blackburn SA, Davis J, Massar K, Correia J, Tsai H-J, et al. Pseudomonas aeruginosa increases the susceptibility of Candida albicans to amphotericin B in dual-species biofilms. J Antimicrob Chemother. 2023;78:2228–41.37522316 10.1093/jac/dkad228
68. Alam F Catlow D Di Maio A Blair JMA Hall RA Candida albicans enhances meropenem tolerance of Pseudomonas aeruginosa in a dual-species biofilm J Antimicrob Chemother 2020 75 925 935 10.1093/jac/dkz514 31865379
Alam F, Catlow D, Di Maio A, Blair JMA, Hall RA. Candida albicans enhances meropenem tolerance of Pseudomonas aeruginosa in a dual-species biofilm. J Antimicrob Chemother. 2020;75:925–35.31865379 10.1093/jac/dkz514
69. Santos-Fernandez E Martin-Souto L Antoran A Areitio M Aparicio-Fernandez L Bouchara J-P Microbiota and fungal-bacterial interactions in the cystic fibrosis lung FEMS Microbiol Rev 2023 47 029 10.1093/femsre/fuad029
Santos-Fernandez E, Martin-Souto L, Antoran A, Areitio M, Aparicio-Fernandez L, Bouchara J-P, et al. Microbiota and fungal-bacterial interactions in the cystic fibrosis lung. FEMS Microbiol Rev. 2023;47:029.10.1093/femsre/fuad029
70. Bigot J Ruffin M Guitard J Vellaissamy S Thorez S Corvol H Effect of flagellin pre-exposure on the inflammatory and antifungal response of bronchial epithelial cells to fungal pathogens J Fungi (Basel) 2022 8 1268 10.3390/jof8121268 36547601
Bigot J, Ruffin M, Guitard J, Vellaissamy S, Thorez S, Corvol H, et al. Effect of flagellin pre-exposure on the inflammatory and antifungal response of bronchial epithelial cells to fungal pathogens. J Fungi (Basel). 2022;8:1268.36547601 10.3390/jof8121268
71. Maturu VN Agarwal R Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta-analysis Clin Exp Allergy 2015 45 1765 1778 10.1111/cea.12595 26177981
Maturu VN, Agarwal R. Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta-analysis. Clin Exp Allergy. 2015;45:1765–78.26177981 10.1111/cea.12595
72. Rammaert B Puyade M Cornely OA Seidel D Grossi P Husain S Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European confederation of medical mycology Transpl Infect Dis 2019 21 e13141 10.1111/tid.13141 31283872
Rammaert B, Puyade M, Cornely OA, Seidel D, Grossi P, Husain S, et al. Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European confederation of medical mycology. Transpl Infect Dis. 2019;21: e13141.31283872 10.1111/tid.13141
73. Abdolrasouli A Bercusson AC Rhodes JL Hagen F Buil JB Tang AYY Airway persistence by the emerging multi-azole-resistant Rasamsonia argillacea complex in cystic fibrosis Mycoses 2018 61 665 673 10.1111/myc.12789 29702751
Abdolrasouli A, Bercusson AC, Rhodes JL, Hagen F, Buil JB, Tang AYY, et al. Airway persistence by the emerging multi-azole-resistant Rasamsonia argillacea complex in cystic fibrosis. Mycoses. 2018;61:665–73.29702751 10.1111/myc.12789
74. Zouhair R Rougeron A Razafimandimby B Kobi A Bouchara J-P Giraud S Distribution of the different species of the Pseudallescheria boydii/Scedosporium apiospermum complex in French patients with cystic fibrosis Med Mycol 2013 51 603 613 10.3109/13693786.2013.770606 23461512
Zouhair R, Rougeron A, Razafimandimby B, Kobi A, Bouchara J-P, Giraud S. Distribution of the different species of the Pseudallescheria boydii/Scedosporium apiospermum complex in French patients with cystic fibrosis. Med Mycol. 2013;51:603–13.23461512 10.3109/13693786.2013.770606
75. Giraud S Pihet M Razafimandimby B Carrère J Degand N Mely L Geosmithia argillacea: an emerging pathogen in patients with cystic fibrosis J Clin Microbiol 2010 48 2381 2386 10.1128/JCM.00047-10 20463155
Giraud S, Pihet M, Razafimandimby B, Carrère J, Degand N, Mely L, et al. Geosmithia argillacea: an emerging pathogen in patients with cystic fibrosis. J Clin Microbiol. 2010;48:2381–6.20463155 10.1128/JCM.00047-10
76. Spahr JE Love RB Francois M Radford K Meyer KC Lung transplantation for cystic fibrosis: current concepts and one center’s experience J Cyst Fibros 2007 6 334 350 10.1016/j.jcf.2006.12.010 17418647
Spahr JE, Love RB, Francois M, Radford K, Meyer KC. Lung transplantation for cystic fibrosis: current concepts and one center’s experience. J Cyst Fibros. 2007;6:334–50.17418647 10.1016/j.jcf.2006.12.010
77. Mills R Rautemaa-Richardson R Wilkinson S Patel L Maitra A Horsley A Impact of airway Exophiala spp. on children with cystic fibrosis J Cyst Fibros 2021 20 702 707 10.1016/j.jcf.2021.03.012 33775601
Mills R, Rautemaa-Richardson R, Wilkinson S, Patel L, Maitra A, Horsley A. Impact of airway Exophiala spp. on children with cystic fibrosis. J Cyst Fibros. 2021;20:702–7.33775601 10.1016/j.jcf.2021.03.012
78. Willger SD Grim SL Dolben EL Shipunova A Hampton TH Morrison HG Characterization and quantification of the fungal microbiome in serial samples from individuals with cystic fibrosis Microbiome 2014 2 40 10.1186/2049-2618-2-40 25408892
Willger SD, Grim SL, Dolben EL, Shipunova A, Hampton TH, Morrison HG, et al. Characterization and quantification of the fungal microbiome in serial samples from individuals with cystic fibrosis. Microbiome. 2014;2:40.25408892 10.1186/2049-2618-2-40
79. Dmitrijeva M Kahlert CR Feigelman R Kleiner RL Nolte O Albrich WC Strain-resolved dynamics of the lung microbiome in patients with cystic fibrosis MBio 2021 12 e02863 e2920 10.1128/mBio.02863-20 33688005
Dmitrijeva M, Kahlert CR, Feigelman R, Kleiner RL, Nolte O, Albrich WC, et al. Strain-resolved dynamics of the lung microbiome in patients with cystic fibrosis. MBio. 2021;12:e02863-e2920.33688005 10.1128/mBio.02863-20
80. Hernández-Hernández F Fréalle E Caneiro P Salleron J Durand-Joly I Accoceberry I Prospective multicenter study of Pneumocystis jirovecii colonization among cystic fibrosis patients in France J Clin Microbiol 2012 50 4107 4110 10.1128/JCM.01974-12 23015669
Hernández-Hernández F, Fréalle E, Caneiro P, Salleron J, Durand-Joly I, Accoceberry I, et al. Prospective multicenter study of Pneumocystis jirovecii colonization among cystic fibrosis patients in France. J Clin Microbiol. 2012;50:4107–10.23015669 10.1128/JCM.01974-12
81. Nevez G Robert-Gangneux F Pougnet L Virmaux M Belleguic C Deneuville E Pneumocystis jirovecii and cystic fibrosis in brittany France Mycopathologia 2018 183 81 87 10.1007/s11046-017-0172-2 28688008
Nevez G, Robert-Gangneux F, Pougnet L, Virmaux M, Belleguic C, Deneuville E, et al. Pneumocystis jirovecii and cystic fibrosis in brittany. France Mycopathologia. 2018;183:81–7.28688008 10.1007/s11046-017-0172-2
82. Gal SL Héry-Arnaud G Ramel S Virmaux M Damiani C Totet A Pneumocystis jirovecii and cystic fibrosis in France Scand J Infect Dis 2010 42 225 227 10.3109/00365540903447000 20085426
Gal SL, Héry-Arnaud G, Ramel S, Virmaux M, Damiani C, Totet A, et al. Pneumocystis jirovecii and cystic fibrosis in France. Scand J Infect Dis. 2010;42:225–7.20085426 10.3109/00365540903447000
83. Green HD Bright-Thomas RJ Mutton KJ Guiver M Jones AM Increased prevalence of Pneumocystis jirovecii colonisation in acute pulmonary exacerbations of cystic fibrosis J Infect 2016 73 1 7 10.1016/j.jinf.2016.05.001 27189843
Green HD, Bright-Thomas RJ, Mutton KJ, Guiver M, Jones AM. Increased prevalence of Pneumocystis jirovecii colonisation in acute pulmonary exacerbations of cystic fibrosis. J Infect. 2016;73:1–7.27189843 10.1016/j.jinf.2016.05.001
84. Sing A Geiger AM Hogardt M Heesemann J Pneumocystis carinii carriage among cystic fibrosis patients, as detected by nested PCR J Clin Microbiol 2001 39 2717 2718 10.1128/JCM.39.7.2717-2718.2001 11427604
Sing A, Geiger AM, Hogardt M, Heesemann J. Pneumocystis carinii carriage among cystic fibrosis patients, as detected by nested PCR. J Clin Microbiol. 2001;39:2717–8.11427604 10.1128/JCM.39.7.2717-2718.2001
85. Pederiva MA Wissmann G Friaza V Morilla R de La Horra C Montes-Cano MA High prevalence of Pneumocystis jirovecii colonization in Brazilian cystic fibrosis patients Med Mycol 2012 50 556 560 10.3109/13693786.2011.645892 22206262
Pederiva MA, Wissmann G, Friaza V, Morilla R, de La Horra C, Montes-Cano MA, et al. High prevalence of Pneumocystis jirovecii colonization in Brazilian cystic fibrosis patients. Med Mycol. 2012;50:556–60.22206262 10.3109/13693786.2011.645892
86. Respaldiza N Montes-Cano MA Dapena FJ de la Horra C Mateos I Medrano FJ Prevalence of colonisation and genotypic characterisation of Pneumocystis jirovecii among cystic fibrosis patients in Spain Clin Microbiol Infect 2005 11 1012 1015 10.1111/j.1469-0691.2005.01276.x 16307556
Respaldiza N, Montes-Cano MA, Dapena FJ, de la Horra C, Mateos I, Medrano FJ, et al. Prevalence of colonisation and genotypic characterisation of Pneumocystis jirovecii among cystic fibrosis patients in Spain. Clin Microbiol Infect. 2005;11:1012–5.16307556 10.1111/j.1469-0691.2005.01276.x
87. Bonnet P Le Gal S Calderon E Delhaes L Quinio D Robert-Gangneux F Pneumocystis jirovecii in patients with cystic fibrosis: a review Front Cell Infect Microbiol 2020 10 571253 10.3389/fcimb.2020.571253 33117730
Bonnet P, Le Gal S, Calderon E, Delhaes L, Quinio D, Robert-Gangneux F, et al. Pneumocystis jirovecii in patients with cystic fibrosis: a review. Front Cell Infect Microbiol. 2020;10: 571253.33117730 10.3389/fcimb.2020.571253
88. Loeffert ST Melloul E Dananché C Hénaff L Bénet T Cassier P Monitoring of clinical strains and environmental fungal aerocontamination to prevent invasive aspergillosis infections in hospital during large deconstruction work: a protocol study BMJ Open 2017 10.1136/bmjopen-2017-018109 29175886
Loeffert ST, Melloul E, Dananché C, Hénaff L, Bénet T, Cassier P, et al. Monitoring of clinical strains and environmental fungal aerocontamination to prevent invasive aspergillosis infections in hospital during large deconstruction work: a protocol study. BMJ Open. 2017. 10.1136/bmjopen-2017-018109.29175886 10.1136/bmjopen-2017-018109
89. Conrad D Haynes M Salamon P Rainey PB Youle M Rohwer F Cystic fibrosis therapy: a community ecology perspective Am J Respir Cell Mol Biol 2013 48 150 156 10.1165/rcmb.2012-0059PS 23103995
Conrad D, Haynes M, Salamon P, Rainey PB, Youle M, Rohwer F. Cystic fibrosis therapy: a community ecology perspective. Am J Respir Cell Mol Biol. 2013;48:150–6.23103995 10.1165/rcmb.2012-0059PS
90. Quinn RA Whiteson K Lim YW Zhao J Conrad D LiPuma JJ Ecological networking of cystic fibrosis lung infections NPJ Biofilms Microbiomes 2016 2 4 10.1038/s41522-016-0002-1 28649398
Quinn RA, Whiteson K, Lim YW, Zhao J, Conrad D, LiPuma JJ, et al. Ecological networking of cystic fibrosis lung infections. NPJ Biofilms Microbiomes. 2016;2:4.28649398 10.1038/s41522-016-0002-1
91. Peschel S Müller CL von Mutius E Boulesteix A-L Depner M NetCoMi: network construction and comparison for microbiome data in R Brief Bioinform 2020 1706 77
Peschel S, Müller CL, von Mutius E, Boulesteix A-L, Depner M. NetCoMi: network construction and comparison for microbiome data in R. Brief Bioinform. 2020;1706:77.
92. Debourgogne A Monpierre L Sy KA Valsecchi I Decousser J-W Botterel F Interactions between bacteria and Aspergillus fumigatus in airways: from the mycobiome to molecular interactions J Fungi (Basel) 2023 9 900 10.3390/jof9090900 37755008
Debourgogne A, Monpierre L, Sy KA, Valsecchi I, Decousser J-W, Botterel F. Interactions between bacteria and Aspergillus fumigatus in airways: from the mycobiome to molecular interactions. J Fungi (Basel). 2023;9:900.37755008 10.3390/jof9090900
93. Briard B Mislin GLA Latgé J-P Beauvais A Interactions between Aspergillus fumigatus and pulmonary bacteria: current state of the field, new data, and future perspective J Fungi (Basel). 2019 10.3390/jof5020048 31212791
Briard B, Mislin GLA, Latgé J-P, Beauvais A. Interactions between Aspergillus fumigatus and pulmonary bacteria: current state of the field, new data, and future perspective. J Fungi (Basel). 2019. 10.3390/jof5020048.31212791 10.3390/jof5020048
94. Melloul E Roisin L Durieux M-F Woerther P-L Jenot D Risco V Interactions of Aspergillus fumigatus and Stenotrophomonas maltophilia in an in vitro mixed biofilm model: does the strain matter? Front Microbiol 2018 10.3389/fmicb.2018.02850 30542331
Melloul E, Roisin L, Durieux M-F, Woerther P-L, Jenot D, Risco V, et al. Interactions of Aspergillus fumigatus and Stenotrophomonas maltophilia in an in vitro mixed biofilm model: does the strain matter? Front Microbiol. 2018. 10.3389/fmicb.2018.02850.30542331 10.3389/fmicb.2018.02850
95. Roisin L Melloul E Woerther P-L Royer G Decousser J-W Guillot J Modulated response of Aspergillus fumigatus and Stenotrophomonas maltophilia to antimicrobial agents in polymicrobial biofilm Front Cell Infect Microbiol 2020 10 574028 10.3389/fcimb.2020.574028 33123497
Roisin L, Melloul E, Woerther P-L, Royer G, Decousser J-W, Guillot J, et al. Modulated response of Aspergillus fumigatus and Stenotrophomonas maltophilia to antimicrobial agents in polymicrobial biofilm. Front Cell Infect Microbiol. 2020;10: 574028.33123497 10.3389/fcimb.2020.574028
96. O’Brien S Fothergill JL The role of multispecies social interactions in shaping Pseudomonas aeruginosa pathogenicity in the cystic fibrosis lung FEMS Microbiol Lett 2017 10.1093/femsle/fnx128 28859314
O’Brien S, Fothergill JL. The role of multispecies social interactions in shaping Pseudomonas aeruginosa pathogenicity in the cystic fibrosis lung. FEMS Microbiol Lett. 2017. 10.1093/femsle/fnx128.28859314 10.1093/femsle/fnx128
97. Ostapska H Le Mauff F Gravelat FN Snarr BD Bamford NC Van Loon JC Co-operative Biofilm Interactions between Aspergillus fumigatus and Pseudomonas aeruginosa through secreted galactosaminogalactan exopolysaccharide J Fungi (Basel) 2022 8 336 10.3390/jof8040336 35448567
Ostapska H, Le Mauff F, Gravelat FN, Snarr BD, Bamford NC, Van Loon JC, et al. Co-operative Biofilm Interactions between Aspergillus fumigatus and Pseudomonas aeruginosa through secreted galactosaminogalactan exopolysaccharide. J Fungi (Basel). 2022;8:336.35448567 10.3390/jof8040336
98. Graeber SY Mall MA The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches Lancet 2023 402 1185 1198 10.1016/S0140-6736(23)01608-2 37699417
Graeber SY, Mall MA. The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches. Lancet. 2023;402:1185–98.37699417 10.1016/S0140-6736(23)01608-2
99. Wainwright CE Elborn JS Ramsey BW Marigowda G Huang X Cipolli M Lumacaftor–Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR N Engl J Med 2015 373 220 231 10.1056/NEJMoa1409547 25981758
Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. Lumacaftor–Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373:220–31.25981758 10.1056/NEJMoa1409547
100. Konstan MW McKone EF Moss RB Marigowda G Tian S Waltz D Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study Lancet Respir Med 2017 5 107 118 10.1016/S2213-2600(16)30427-1 28011037
Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2017;5:107–18.28011037 10.1016/S2213-2600(16)30427-1
101. Harris JK Wagner BD Zemanick ET Robertson CE Stevens MJ Heltshe SL Changes in airway microbiome and inflammation with ivacaftor treatment in patients with cystic fibrosis and the G551D mutation Ann Am Thorac Soc 2020 17 212 220 10.1513/AnnalsATS.201907-493OC 31604026
Harris JK, Wagner BD, Zemanick ET, Robertson CE, Stevens MJ, Heltshe SL, et al. Changes in airway microbiome and inflammation with ivacaftor treatment in patients with cystic fibrosis and the G551D mutation. Ann Am Thorac Soc. 2020;17:212–20.31604026 10.1513/AnnalsATS.201907-493OC
102. Graeber SY Boutin S Wielpütz MO Joachim C Frey DL Wege S Effects of lumacaftor–ivacaftor on lung clearance index, magnetic resonance imaging, and airway microbiome in Phe508del homozygous patients with cystic fibrosis Ann Am Thorac Soc 2021 18 971 980 10.1513/AnnalsATS.202008-1054OC 33600745
Graeber SY, Boutin S, Wielpütz MO, Joachim C, Frey DL, Wege S, et al. Effects of lumacaftor–ivacaftor on lung clearance index, magnetic resonance imaging, and airway microbiome in Phe508del homozygous patients with cystic fibrosis. Ann Am Thorac Soc. 2021;18:971–80.33600745 10.1513/AnnalsATS.202008-1054OC
103. Frost FJ Nazareth DS Charman SC Winstanley C Walshaw MJ Ivacaftor is associated with reduced lung infection by key cystic fibrosis pathogens. A cohort study using national registry data Ann Am Thorac Soc 2019 16 1375 1382 10.1513/AnnalsATS.201902-122OC 31319678
Frost FJ, Nazareth DS, Charman SC, Winstanley C, Walshaw MJ. Ivacaftor is associated with reduced lung infection by key cystic fibrosis pathogens. A cohort study using national registry data. Ann Am Thorac Soc. 2019;16:1375–82.31319678 10.1513/AnnalsATS.201902-122OC
104. Heltshe SL Mayer-Hamblett N Burns JL Khan U Baines A Ramsey BW Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor Clin Infect Dis 2015 60 703 712 10.1093/cid/ciu944 25425629
Heltshe SL, Mayer-Hamblett N, Burns JL, Khan U, Baines A, Ramsey BW, et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis. 2015;60:703–12.25425629 10.1093/cid/ciu944
105. Bessonova L Volkova N Higgins M Bengtsson L Tian S Simard C Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor Thorax 2018 73 731 740 10.1136/thoraxjnl-2017-210394 29748252
Bessonova L, Volkova N, Higgins M, Bengtsson L, Tian S, Simard C, et al. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax. 2018;73:731–40.29748252 10.1136/thoraxjnl-2017-210394
106. Currie AJ Main ET Wilson HM Armstrong-James D Warris A CFTR modulators dampen aspergillus-induced reactive oxygen species production by cystic fibrosis phagocytes Front Cell Infect Microbiol 2020 10 372 10.3389/fcimb.2020.00372 32793514
Currie AJ, Main ET, Wilson HM, Armstrong-James D, Warris A. CFTR modulators dampen aspergillus-induced reactive oxygen species production by cystic fibrosis phagocytes. Front Cell Infect Microbiol. 2020;10:372.32793514 10.3389/fcimb.2020.00372
107. Enaud R Lussac-Sorton F Charpentier E Velo-Suárez L Guiraud J Bui S Effects of lumacaftor–ivacaftor on airway microbiota-mycobiota and inflammation in patients with cystic fibrosis appear to be linked to Pseudomonas aeruginosa chronic colonization Microbiol Spectr 2023 11 e0225122 10.1128/spectrum.02251-22 36971560
Enaud R, Lussac-Sorton F, Charpentier E, Velo-Suárez L, Guiraud J, Bui S, et al. Effects of lumacaftor–ivacaftor on airway microbiota-mycobiota and inflammation in patients with cystic fibrosis appear to be linked to Pseudomonas aeruginosa chronic colonization. Microbiol Spectr. 2023;11: e0225122.36971560 10.1128/spectrum.02251-22
